Fiche du document
2022
- doi: 10.3389/fendo.2022.794512
- issn: 1664-2392
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.3389/fendo.2022.794512
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35399933
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1664-2392
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_8F80FCDEF66D5
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Therapy Tyrosine protein kinase Tyrosine kinase Hydroxyaryl-protein kinase Tyrosine-specific protein kinase Tyrosylprotein kinase Tumours Neoplasms Gleevec (Trademark)Citer ce document
S. Papadopoulos et al., « Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients. », Serveur académique Lausannois, ID : 10.3389/fendo.2022.794512
Métriques
Partage / Export
Résumé
Tyrosine kinase inhibitors (TKIs) are nowadays a valuable treatment of desmoid tumors, a rare mesenchymal neoplasm. Although many side effects of imatinib and pazopanib, commonly or rarely occurring, have been described, reactional lymphadenopathy has not yet been reported. In this publication, we report two cases of patients with desmoid tumors, treated with pazopanib and imatinib, who developed reactional lymphadenopathy. As this side effect is presented as a newly formed mass, it can result in new diagnostic questions and added imaging tests and can even lead to discontinuation of the treatment. This report may help the clinicians facing similar problems adopt a "watch and wait" approach.